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Abstract
Background: Most cytokines signal through heteromeric receptor complexes consisting of two or more different
receptor subunits. Fusion proteins of the extracellular parts of receptor subunits turned out to be promising
cytokine inhibitors useful in anti-cytokine therapy and cytokine research.
Results: We constructed receptor fusion proteins (RFP) consisting of the ligand binding domains of the murine
oncostatin M (mOSM) receptor subunits mOSMR and mgp130 connected by a flexible linker as potential mOSM
inhibitors. mgp130 is a shared cytokine receptor that is also used by other cytokines such as IL-6 and leukemia
inhibitory factor (LIF). In this study we compare four types of mOSM-RFPs that contain either domains D1-D3 or
domains D2-D3 of mgp130 and are arranged in two ways. Domain D1 of mgp130 turned out to be dispensable
for mOSM-binding. However, the arrangement of the two receptor subunits is essential for the inhibitory activity.
We found mOSM induced STAT3 phosphorylation to be suppressed only when the mOSMR fragment was fused in
front of the mgp130 fragment.
Conclusions: mOSM-RFP consisting of D1-D4 of mOSMR and D2-D3 of mgp130 is a highly potent and specific
inhibitor of mOSM. Since mOSM-RFP is encoded by a single gene it offers numerous possibilities for specific
cytokine inhibition in gene delivery approaches based on viral vectors, transgenic animals and finally gene therapy.
Background
Cytokines are central mediators of the immune system.
Anti-cytokine therapies are aimed at the specific inhibi-
tion of a cytokine that has been identified to be critically
involved in the initiation, maintenance or progression of
a disease. Most cytokines signal through heteromeric
receptors consisting of two different receptor chains.
We have developed a new class of cytokine inhibitors
based on the fusion of the ligand-binding domains of
cytokine receptors by a flexible linker [1]. The prototy-
pic receptor fusion protein (RFP) directed against
human interleukin-6 (hIL-6-RFP) turned out to be a
highly specific and highly potent inhibitor of hIL-6 [2].
Based on this original approach further RFP have been
generated by others for the inhibition of human oncos-
tatin M [3] and most recently human interleukin-31 [4].
In a different but related approach so called cytokine
traps have been generated by the fusion of soluble
receptors through Fc-fragments [5].
For the validation of the RFP approach in murine animal
models in vivo RFP directed against murine cytokines are
required. RFPs based on human receptor proteins are not
useful for this purpose because murine cytokines usually
do not bind to the human receptors. Therefore, we con-
centrated on the generation of receptor fusion proteins for
the inhibition of murine cytokines. We described mLIF-
RFP [6] for the inhibition of murine leukemia inhibitory
factor (mLIF) and recently mIL-6-RFP [7] for the inhibi-
tion of murine IL-6 (mIL-6).
Oncostatin M (OSM) is a pro-inflammatory cytokine
of the IL-6 family implicated in rheumatoid arthritis [8],
lung fibrosis [9] and skin disease [10]. OSM is secreted
by activated T-cells [11], macrophages [12], neutrophils
[13] and synovial fibroblasts from patients with rheuma-
toid arthritis [14]. The murine OSM receptor consists of
two receptor proteins [15], the OSM-specific OSMR and
gp130, the common signalling receptor subunit of the
IL-6 family of cytokines. OSM signals through the Jak/
STAT pathway resulting in the activation of STAT3 and
STAT5. ERK1/2 and p38 MAP kinases are also activated
in response to OSM [16].
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Here we describe the generation of a novel inhibitor
for murine OSM, mOSM-RFP, that is based on the
fusion of murine OSMR and murine gp130 fragments.
mOSM-RFP will be a useful tool for the investigation of
the role of OSM in murine models of human diseases.
Results
1. Design and expression of murine oncostatin M
receptor fusion proteins (mOSM-RFPs)
We generated four different murine oncostatin M recep-
tor fusion proteins (mOSM-RFPs) (Figure 1A). The first
protein (mOSM-RFP) is built up in analogy to the
recently published receptor fusion protein for the inhibi-
tion of murine LIF (mLIF-RFP) [6]. It consists of the
four N-terminal domains of the murine OSM receptor
(mOSMR) and domains D2 and D3 of murine gp130
(mgp130) connected by a flexible polypeptide linker. We
[17] and others [18] have shown that the N-terminal
domain D1 of gp130 is dispensable for signal transduc-
tion in response to OSM. Another report suggests a
functional role of D1 of gp130 in OSM-binding [19].
Moreover, we have shown that the addition of a single
domain, even if not involved in ligand-binding, can
strongly enhance the expression of a receptor fusion
protein [7]. Therefore, we decided to construct another
fusion protein that includes D1 of mgp130 (mOSM-RFP
+D1, Figure 1A). To assess the importance of the order
of the receptor fragments we also constructed inverted
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Figure 1 Construction and expression of mOSM-RFPs. (A) Schematic representation of the four OSM-RFPs analyzed in this study.
(B) Supernatants of HEK293 cells were collected 48 h after transfection with expression vectors encoding the indicated mOSM-RFPs. 10-fold
concentrated supernatants were analyzed by SDS-PAGE and Western blotting using a FLAG antibody.
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receptor fusion proteins with the mgp130 fragment pre-
ceding the mOSMR fragment (i-mOSM-RFP and i-
mOSM-RFP+D1, Figure 1A).
Human embryonic kidney (HEK293) cells were trans-
fected with expression vectors encoding the four
mOSM-RFPs. Supernatants of the cells were concen-
trated 10-fold and analyzed by Western blotting using
an antibody directed against the FLAG-tag of the
mOSM-RFPs. All four proteins were expressed (Figure
1B) indicating that neither the presence of D1 of gp130
nor the order of the receptor fragments has a major
influence on protein expression. However, the yield of
i-mOSM-RFP was always somewhat lower compared to
the other fusion proteins. The apparent molecular
masses are in the range of 120 to 140 kDa which is in
agreement with the expected molecular masses of the
glycosylated mOSM-RFPs.
2. Inhibitory activity and specificity of mOSM-RFPs
To analyze the activities of the mOSM-RFPs, murine
embryonic fibroblasts (MEF) were stimulated with
mOSM, mLIF and mIL-6 plus murine soluble IL-6
receptor (sR) in the presence of concentrated superna-
tants of HEK293 cells transfected with the expression
vectors encoding the mOSM-RFPs or mock vector.
Lysates of the MEF were analyzed for tyrosine phos-
phorylation of STAT3 by Western blotting (Figure 2A).
Both mOSM-RFP and mOSM-RFP+D1 block the activ-
ity of mOSM but not of mLIF or mIL-6/sR indicating
that these receptor fusion proteins are specific inhibitors
of mOSM. Most interestingly, the inverted receptor
fusion proteins are devoid of any activity under the con-
ditions used in this assay. Therefore, in the following
experiment only mOSM-RFP and mOSM-RFP+D1 were
used.
MEF were stimulated with increasing amounts of
mOSM in the presence of concentrated supernatants of
HEK293 cells transfected with the expression vectors
encoding mOSM-RFP, mOSM-RFP+D1 or mock vector.
Lysates of the MEF were analyzed for tyrosine phos-
phorylation of STAT3 by Western blotting (Figure 2B).
As soon as the mOSM concentration exceeds 200 ng/ml
STAT3 activation is also detectable in the presence of
the mOSM-RFPs. Thus, the tested mOSM-RFPs are
saturable. This speaks for mOSM-binding in solution
rather than blocking of the membrane-bound cellular
receptors by a complex of mOSM and OSM-RFPs. This
experiment also shows that mOSM-RFP and mOSM-
RFP+D1 have comparable inhibitory activities. No
increase in the STAT3 phosphorylation with increasing
mOSM concentrations is seen in the mock lanes
because at 5 ng/ml mOSM the cellular response is
already saturated.
To test the inhibitory activity of mOSM-RFP on sus-
tained STAT3 activation Fao rat hepatoma cells were
stimulated with mOSM for prolonged periods of times
(Figure 2C). Even after 8 h of stimulation mOSM-RFP
reduces STAT3 activation to background levels.
3. mOSM-RFP blocks OSM-induced nuclear accumulation
of STAT3 and SOCS3 gene induction
Two further experiments were performed to analyze
whether STAT3 responses downstream of tyrosine
phosphorylation namely STAT3 nuclear accumulation
and STAT3-mediated gene induction are blocked
by mOSM-RFP. MEF lacking endogenous STAT3
(MEFΔSTAT3) were stably transfected with STAT3-eGFP.
These cells show the typical distribution of latent
STAT3 which is found in the cytoplasm as well as in
the nucleus [20] (Figure 3A). Upon addition of mOSM-
RFP the distribution of STAT3-eGFP does not change.
Stimulation with mOSM leads to rapid nuclear accumu-
lation of STAT3-eGFP. Nuclear accumulation of
STAT3-eGFP is blocked in the presence of mOSM-RFP.
The feedback inhibitor SOCS3 is a well established
STAT3 target gene. SOCS3 gene induction in response
to mOSM was measured by quantitative real-time PCR
(qrt-PCR) (Figure 3B). The concentration of mOSM-
RFP was estimated by Western blot titration taking
advantage of the known concentration of another
FLAG-tagged protein (Additional file 1). Therefore, in
this and the following assays the molecular ratios of
mOSM and mOSM-RFP could be properly adjusted. At
a 10- and 5-fold molar excess mOSM-RFP completely
inhibits mOSM mediated induction of the SOCS3 gene.
Even at a molecular ratio of 1:1 most of the mOSM
response is blocked by mOSM-RFP. Thus, mOSM-RFP
is a specific and potent inhibitor of mOSM activity.
4. Comparison of mOSM-RFP with a mOSM neutralizing
antibody
The inhibitory potency of mOSM-RFP was compared
with a commercially available, affinity-purified neutraliz-
ing polyclonal mOSM antibody (mOSM-ab). MEF were
stimulated with a constant amount of mOSM and differ-
ent concentrations of mOSM-RFP (Figure 4A). In agree-
ment with the experiment shown before (Figure 3B) a
10- to 5-fold molar excess of mOSM-RFP is sufficient to
block mOSM activity. Even at a 1:1 ratio the STAT3
phosphorylation is strongly reduced. When a similar
experiment is performed with mOSM-ab instead of
mOSM-RFP a 50- to 100-fold molar excess of the anti-
body is needed to achieve a marked reduction of
STAT3 phosphorylation. Thus, mOSM-RFP is a much
more potent mOSM inhibitor than an affinity-purified
polyclonal antibody.
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Figure 2 Inhibitory activities and specificity of mOSM-RFPs. (A) MEF were stimulated for 20 min with mOSM (5 ng/ml), mLIF (5 ng/ml) or
mIL-6 (20 ng/ml) and murine soluble IL-6 receptor (sR, 500 ng/ml) in the presence of 5% of 10-fold concentrated supernatants of HEK293 cells
expressing the respective mOSM-RFPs (resulting in a 6-fold molar surplus of mOSM-RFPs over mOSM) or of mock-transfected cells as indicated.
(B) MEF were stimulated for 20 min with varying amounts of mOSM in the presence of 5% of 10-fold concentrated supernatants of HEK293 cells
expressing mOSM-RFP or mOSM-RFP+D1 or of mock-transfected cells as indicated. Cellular lysates were analyzed for tyrosine phosphorylation of
STAT3 and total STAT3 by Western blotting. (C) Fao hepatoma cells were stimulated for the indicated times with mOSM (5 ng/ml) in the
presence of 2% of 10-fold concentrated supernatants of HEK293 cells expressing mOSM-RFP or corresponding supernatant of mock-transfected
cells as indicated. Cellular lysates were analyzed for tyrosine phosphorylation of STAT3 and total STAT3 by Western blotting.
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Figure 3 Effect of mOSM-RFP on mOSM-induced nuclear translocation of STAT3, STAT3-mediated gene induction. (A) MEFΔSTAT3 stably
transfected with STAT3-eGFP were stimulated with 5 ng/ml mOSM for 20 min in the presence of 5% of 10-fold concentrated supernatant
containing mOSM-RFP or supernatant from mock transfected cells (mock SN) as indicated. Cells were fixed and analyzed by confocal microscopy.
Scale bars represent 10 μm. (B) MEF were stimulated for 45 min with varying amounts of mOSM in the presence of mOSM-RFP as indicated.
Induction of mSOCS3 mRNA was quantified by qrt-PCR. mHPRT mRNA served as an internal standard.
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5. Analysis of mOSM/mOSM-RFP complexes by blue-
native PAGE
Complexes formed between mOSM and mOSM-RFPs
were analyzed by blue-native PAGE (bn-PAGE). For this
purpose mOSM was preincubated with the four differ-
ent mOSM-RFPs in the presence of an excess of bovine
serum albumin (120 μg/ml). Proteins and protein com-
plexes were separated by bn-PAGE and analyzed by
Western blotting with a FLAG antibody for the detec-
tion of the OSM-RFPs (Figure 5A, upper panel) and
after stripping of the blot with a mOSM antibody (Fig-
ure 5A, lower panel). Upon addition of mOSM no
shifted bands of mOSM-RFP and mOSM-RFP+D1 are
visible. However, the bands are weaker in the lanes
where mOSM has been added (Figure 5A, upper panel,
compare lanes 2, 3 and 4,5).
Detection of mOSM (Figure 5A, lower panel) reveals
that in the presence of mOSM-RFP or mOSM-RFP+D1
the band of mOSM is completely shifted to approxi-
mately the height of the receptor fusion proteins.
mOSM is only partially shifted by i-mOSM-RFP and i-
mOSM-RFP+D1 but to a much higher apparent molecu-
lar mass compared to the free i-mOSM-RFPs. The
receptor fusion proteins are not detectable in the shifted
bands. Quantitative analysis of the blots revealed that i-
mOSM-RFP and i-mOSM-RFP+D1 have a considerably
lower capacity in shifting mOSM than the mOSM-RFPs
(data not shown).
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Figure 4 Comparison of the activities of mOSM-RFP and a mOSM-neutralizing antibody. MEF were stimulated for 20 min with 5 ng/ml
mOSM in the presence of (A) mOSM-RFP or (B) a neutralizing polyclonal mOSM antibody at varying concentrations as indicated. Cellular lysates
were analyzed for tyrosine phosphorylation of STAT3 and total STAT3 by Western blotting. GAPDH was detected as another loading control.
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Figure 5 Complexes of mOSM-RFPs and mOSM analyzed by bn-PAGE. (A) 35 ng of mOSM were incubated with 200 ng of the respective
mOSM-RFP (with the exception of i-mOSM-RFP that is less efficiently expressed and therefore 200 ng could not be achieved) in 50 μl for 30
min. Subsequently Coomassie Brilliant blue G-250 was added and the protein complexes were separated on a native gradient gel (4-16% PAA).
After blotting of the proteins to a PVDF membrane mOSM-RFPs were detected using a FLAG antibody (upper panel). After stripping of the blot
mOSM was detected using a mOSM antibody (middle panel). (B) bn-PAGE was performed as described in (A) with the protein amounts
indicated in the figure. After blotting, detection of the proteins was performed with primary goat-anti-mOSM and mouse-anti-flag antibodies
followed by secondary rabbit-anti-goat-Cy2 and donkey-anti-mouse-Cy3 antibodies. Fluorescence was detected with a fluorescence scanner.
Afterwards the mOSM antibody was visualized by ECL using a matching HRP-conjugated secondary antibody.
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To clarify the identities of the bands another bn-
PAGE was performed with different concentrations of
mOSM-RFP and i-mOSM-RFP+D1. After blotting of the
gel the FLAG-tags of the fusion proteins and mOSM
were detected using antibodies with different fluorescent
labels. The blots were analyzed using a fluorescence
scanner (Figure 5B). mOSM shifted by mOSM-RFP is
visible (Figure 5B, upper left image) although the fluor-
escence detection is not as sensitive as the enhanced
chemiluminescence detection (Figure 5B, upper right
image) where the mOSM shifted by i-mOSM-RFP+D1
and the non-shifted mOSM are also visible. The fluores-
cence detection of the FLAG-tag (Figure 5B, lower left
image) and the overlay of the two fluorescence detec-
tions (Figure 5B, lower right image) reveal that the
shifted mOSM is of lower electrophoretic mobility than
mOSM-RFP. Apparently, the FLAG-tag of mOSM-RFP
is nearly completely masked upon complex formation
with mOSM so that only very faint bands are visible (e.
g. Figure 5B, lower panels, lane 6). From the electro-
phoretic mobilities and the shift of the bands we con-
clude that mOSM is bound by mOSM-RFP or mOSM-
RFP+D1 in a 1:1 complex (Figure 6A). We propose that
mOSM binds to dimers of the i-mOSM-RFPs (Figure
6B). A propensity for dimer formation of the i-mOSM-
RFPs is evident from SDS-PAGE where the dimers can
be detected even under denaturing conditions (Addi-
tional file 2).
Discussion
We developed novel receptor fusion proteins for the
inhibition of murine OSM. The receptor fusion protein
mOSM-RFP consisting of domains D1-D4 of mOSMR
connected by a flexible peptide linker to domains D2-
D3 of mgp130 is a potent inhibitor of mOSM with
respect to STAT3 phosphorylation (Figure 2), STAT3
nuclear translocation and STAT3-mediated gene induc-
tion (Figure 3). Addition of D1 of mgp130 does neither
improve protein expression (Figure 1) nor inhibitory
activity (Figure 2B) confirming that domains D2-D3 of
gp130 are sufficient for complex formation with OSM
[17,21]. Our fusion proteins for the inhibition of murine
OSM differ from a previously described fusion protein
for the inhibition of human OSM that consisted of the
first 428 amino acids of soluble hOSMR fused to 51
amino acids (aa 767-817) of hgp130 [3]. A more recently
published receptor fusion protein for the inhibition of
human IL-31 consisting of D1-D4 of hOSMR and D1-
D2 of hIL-31R [4] is built up in analogy to our formerly
described mLIF-RFP [6] and therefore resembles
mOSM-RFP described in this study. Previously
described cytokine traps consist of soluble receptors
fused to Fc-fragments. These cytokine traps require the
expression of two genes. After protein expression,
homodimers must be separated from the desired hetero-
dimeric proteins [5].
Compared to mOSM-RFP and mOSM-RFP+D1 the
inverted proteins i-mOSM-RFP and i-mOSM-RFP+D1
are weak OSM-binding proteins (Figure 5) and therefore
unsuited as inhibitors (Figure 2A). This initially puzzling
observation might be explained at least in part by the
analysis of OSM/OSM-RFP complexes with bn-PAGE
(Figure 5). mOSM-RFP and mOSM-RFP+D1 when
bound to mOSM form a 1:1 complex that is in agree-
ment with the proposed stoichiometry of the OSM
receptor complex consisting of one molecule of each
OSM, OSMR and gp130 [22]. When the domains of
OSMR and gp130 are arranged in a way as proposed for
the closely related LIF receptor complex ([22], Figure
6A) it is evident that the C-terminus of domain D4 of
OSMR is much closer to the N-terminus of gp130 than
the C-terminus of gp130 to the N-terminus of OSMR.
The latter distance is relevant for the inverted mOSM-
RFPs and might be too long to be bridged by the 43
amino acid linker used in our fusion proteins. Therefore,
the complex adopts an alternative conformation of 2:2
stoichiometry as shown in Figure 6B. Apparently, this
alternative complex is of lower affinity than the native
receptor complex.
Gp130 is the common receptor subunit of the IL-6
family of cytokines comprising IL-6, OSM, LIF, IL-11,
IL-27, ciliary neurotrophic factor, cardiotrophin-1, cardi-
otrophin-like cytokine and neuropoetin [23]. None of
these cytokines binds with high affinity to gp130 alone.
For high affinity-binding a second more specific receptor
subunit is required [24]. Accordingly, mOSM-RFP is a
mOSM-specific inhibitor that does not inhibit the
related cytokines mIL-6 and mLIF (Figure 2A) that
require mIL-6R and mLIFR, respectively, for high affi-
nity-binding. Conversely, the mIL-6 inhibitor mIL-6-
RFP and the mLIF inhibitor mLIF-RFP do not inhibit
mOSM [6,7]. Thus, shared cytokine receptors are useful
for the design of specific cytokine inhibitors. For this
reason, the receptor fusion protein approach can be
applied to the remaining cytokines of the IL-6 family
but also to cytokines that use other shared receptors
such as the IL-2 family and the IL-3 family of cytokines
using the common g-chain and the common b-chain,
respectively. mOSM-RFP will be a useful tool to deci-
pher the controversially discussed role of mOSM in
murine models of inflammatory diseases [8].
Conclusions
The functional OSM-RFPs presented in this study and
the previously described RFPs are highly specific and
potent cytokine inhibitors. RFPs are encoded by a single
gene. This offers an advantage with respect to gene
delivery approaches compared to cytokine traps based
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on soluble receptors fused to Fc-tags [5] or antibodies
which are composed of two different protein chains.
RFPs can be conveniently expressed as single gene con-
structs by viral gene transfer or in transgenic animals.
Thus, RFPs offer numerous possibilities to test the effect
of cytokine inhibition in immune responses, in animal
models of human diseases and finally in gene therapy.
Methods
Recombinant plasmids
The expression vectors pcDNA5/FRT/TO-mOSM-RFP,
pcDNA5/FRT/TO-mOSM-RFP+D1, pcDNA5/FRT/TO-
i-mOSM-RFP and pcDNA5/FRT/TO-i-mOSM-RFP+D1
were constructed using previously described pSVL-
mLIF-RFP [6] and pcDNA3.1-mIL6-RFP [7] expression
vectors and the pcDNA5/FRT/TO vector of the Flp-In
system (Invitrogen, USA). The mOSMR fragment was
amplified by RT-PCR from total MEF mRNA.
All expression constructs of the mOSM-RFPs are built
up similarly on the backbone of the pcDNA5/FRT/TO
vector. A Kozak consensus sequence (GCC ACC) is fol-
lowed by the leader sequence of preprotrypsin for opti-
mal mRNA translation and protein secretion,
respectively. The receptor fragments are joined by a poly-
peptide linker of 43 amino acids (PGGSAAATRG
SAGSGGSATG SGSAAGSGDS VAAGSGGGSG SAS).
OSM-RFP and OSM-RFP+D1 contain a C-terminal
FLAG-tag (DYKDDDDK), the inverted OSM-RFPs
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Figure 6 Proposed modes of action of mOSM-RFPs. (A) Arrangement of the domains of mOSMR and mgp130 in analogy to the closely
related LIF receptor complex [22]. The green line depicts the linker in the functional inhibitors mOSM-RFP and mOSM-RFP+D1, the red line
depicts the required linker for functional inverted mOSM-RFPs. (B) Schematic representation of a heterotetrameric complex of i-mOSM-RFP or
i-mOSM-RFP+D1 with mOSM. Note that in three dimensions the heterotetrameric complex can be arranged in a way that the linkers are much
shorter.
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contain an additional hexa-histidine-tag. The mOSMR-
fragment is identical in all four mOSM-RFPs and covers
Glu24-Pro427 corresponding to domains D1-D4.
Domains D2-D3 and domains D1-D3 of mgp130 encom-
pass Ser122-Pro324 and Gln23-Pro324, respectively.
Cytokines, cytokine receptors and antibodies
Murine OSM, murine IL-6 and murine soluble IL-6Ra
(sR) were purchased from R&D Systems (MN, USA),
murine LIF (ESGRO®) from Chemicon (CA, USA). The
neutralizing goat anti-mOSM antibody was purchased
from R&D Systems (MN, USA), an IgG control antibody
from Immunotools (Friesoythe, Germany).
Cell culture and transfection
Murine embryonic fibroblasts (MEF) and human
embryonic kidney cells (HEK293) were cultivated in
Dulbecco’s Modified Eagle Medium (DMEM) with Glu-
taMax™ (Invitrogen, CA, USA) supplemented with 10%
FCS, 100 U/ml penicillin and 100 μg/ml streptomycin
(BIO-Whittaker, Verviers, Belgium). For the cultivation
of Fao rat hepatoma cells DMEM/F12 was used. The
cells were incubated at 37°C in a water-saturated atmo-
sphere at 5% CO2. HEK293 cells were transfected with
TransIT® LT-1 transfection reagent (Mirus, WI, USA)
in a ratio of 1 μg DNA to 3 μl transfection reagent.
Medium was exchanged to DMEM with GlutaMax™
without FCS after 4 hours. Supernatants were harvested
after 48 h, cleared by centrifugation and 10-fold concen-
trated in Vivaspin 20 centrifugal concentrators (Sartor-
ius, Göttingen, Germany).
Quantification of mOSM-RFP by Western blotting
FLAG-tagged OSM-RFP was quantified by calibration
with known amounts of FLAG-tagged hIL-6-RFP by
Western blotting using a FLAG antibody (SIGMA-
Aldrich, Taufkirchen, Germany). The intensity of immu-
nodetected bands was quantified using the Fujifilm Mul-
tiGauge software.
Preparation of cell lysates, SDS-PAGE and
immunoblotting
MEF or Fao cells were grown on 6-well plates to 70%
confluence. A mixture of cytokine and mOSM-RFP, neu-
tralizing mOSM antibody or control supernatant, respec-
tively, was preincubated in 1 ml DMEM for 30 min and
afterwards added to the cells for 20 min. Subsequently,
cells were lysed with RIPA lysis buffer (50 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40,
1 mM NaF, 15% glycerol, 20 mM b-glycerophosphate, 1
mM Na3VO4, 0.25 mM phenylmethylsulfonylfluoride, 5
μg/ml aprotinin, and 1 μg/ml leupeptin). The lysates
were analyzed by Western blotting using antibodies
directed against phosphotyrosine705-STAT3 (Cell
Signaling Technology, MA, USA), STAT3 (BD Transduc-
tion Laboratories, CA, USA), GAPDH (Santa Cruz, CA,
USA) and HRP conjugated secondary antibodies (Dako,
Hamburg, Germany). All first antibodies were used in a
1:1.000 dilution, all secondary antibodies in a 1:2.000
dilution in TBS-N (20 mM Tris-HCl, pH 7.6, 137 mM
NaCl and 0.1% Nonidet P-40). Bound antibodies were
detected by chemiluminescence (ECL, Millipore, MA,
USA). Membranes were stripped in 62.5 mM Tris-HCl,
pH 7.6 containing 2% SDS and 0.08% b-mercaptoethanol
for 25 min at 70°C before a second detection was
performed.
Blue-native PAGE
mOSM and concentrated supernatants with the respective
mOSM-RFP were preincubated for 30 min at RT in the
presence of 120 μg/ml bovine serum albumin to allow for-
mation of protein complexes which were subsequently
separated on native 4-16% bis-tris gels in running buffer
containing Coomassie Brilliant Blue G-250. Gels were ana-
lyzed by Western blotting using antibodies directed
against mOSM (goat-anti-mOSM, R&D Systems, MN,
USA), FLAG (mouse-anti-flag, SIGMA-Aldrich, Tauf-
kirchen, Germany) and HRP conjugated secondary antibo-
dies for ECL detection or rabbit-anti-goat-Cy2 and
donkey-anti-mouse-Cy3 for fluorescence detection (Dako,
Hamburg, Germany). Fluorescence was detected with a
fluorescence scanner (Typhoon, Amersham). Novex bis-
tris gels (4-16%), loading and running buffers were pur-
chased from Invitrogen™ (NativePAGE™, CA, USA).
Confocal fluorescence microscopy and live cell imaging
The confocal imaging was performed with a Zeiss LSM
510Meta confocal microscope (Zeiss, Jena, Germany).
eGFP fluorescence was detected using the 488 nm line
of the argon laser, a 488 nm dichroic mirror and a 500-
530 nm bandpass filter. MEFΔSTAT3 cells stably trans-
fected with STAT3-eGFP were cultured on glass cover-
slips for 48 h. mOSM and concentrated supernatant
containing mOSM-RFP were preincubated in 1 ml
DMEM for 30 min at RT. Cells were stimulated for 20
min or left untreated. For fixation the cells were incu-
bated in 3.7% paraformaldehyde for 15 min and washed
twice with PBS containing 1 mM MgCl2 and 0.1 mM
CaCl2 (PBS
++). Afterwards the cells were quenched with
50 mM NH4Cl in PBS
++ for 5 min, dipped in water and
mounted with ImmuMount (Shandon, PA, USA).
Quantitative real-time PCR
MEF were grown on 6-well plates to 70% confluence.
After preincubation of mOSM and mOSM-RFP in 1 ml
DMEM for 30 min MEF were stimulated for 45 min
and subsequently lysed. RNA was extracted using the
RNeasy Kit (Qiagen, Hilden, Germany). After reverse
Brolund et al. BMC Biotechnology 2011, 11:3
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transcription using Omniscript-RT-PCR-Kit (Qiagen,
Hilden, Germany) cDNA was amplified in duplicates in
a Rotor-Gene Q (Qiagen, Hilden, Germany) using speci-
fic primers for mSOCS3 (Mm00545913_s1) and
mHPRT (Mm015453399_m1) as internal standard (Taq-
Man® Gene Expression Assay, Applied Biosystems, CA,
USA). PCR reaction was carried out in a 20 μl reaction
volume in the presence of 25 ng cDNA and 1 μl of pri-
mer mixture. Thermal cycling was initiated with 2 min
incubation at 50°C and 10 min at 95°C followed by 40
cycles of 95°C for 15 s and 60°C for 60 s. The ΔCt
method was used for quantification.
Additional material
Additional file 1: Quantification of mOSM-RFP.
Additional file 2: i-mOSM-RFPs form dimers.
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